Exploring the molecular mechanism of Suoquan pill in the treatment of diabetic kidney disease based on network pharmacology, molecular docking, in vitro experiment

被引:0
|
作者
Yan, Zi-Jie [1 ]
Kang, Yu [2 ]
Liu, Shu-Man [1 ]
Wang, Fang-Yu [3 ]
Xiao, Man [4 ]
Xie, Yi-Qiang [1 ]
机构
[1] Hainan Med Univ, Coll Tradit Chinese Med, 4 Xue Yuan Rd, Haikou 571199, Peoples R China
[2] Heilongjiang Acad Tradit Chinese Med, Grad Sch, Harbin 150001, Peoples R China
[3] Hainan Med Univ, Coll Pharm, Dept Pharmacol, Haikou 571199, Peoples R China
[4] Hainan Med Univ, Key Lab Biochem & Mol Biol, 4 Xue Yuan Rd, Haikou 571199, Peoples R China
来源
TRADITIONAL MEDICINE RESEARCH | 2024年 / 9卷 / 11期
基金
中国国家自然科学基金;
关键词
traditional Chinese medicine; diabetic kidney disease; Suoquan pill; network analysis; molecular docking; PLATELET-ACTIVATING-FACTOR; MESANGIAL CELLS; NEPHROPATHY; SRC; INHIBITION; PROGRESSION; PATHWAY; FAMILY; SLOWS;
D O I
10.53388/TMR20240105002
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Diabetic kidney disease (DKD) is a microvascular complication of diabetes mellitus and is the main cause of end-stage renal failure. Suoquan pills (SQP) has a variety of pharmacological activities and multiple therapeutic effects, and it is used clinically as a basic formula for the treatment of DKD. Methods: Public databases were used to identify SQP compounds and the potential targets of SQP and DKD. A drug-component-therapeutic target network was constructed. Protein-protein interaction network analysis, Gene Ontology functional analysis, and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were used to analyse the potential molecular mechanisms of SQP based on common targets of drugs and diseases. Molecular docking simulations were conducted to confirm the binding abity of the core compounds to key targets. The efficacy and predicted molecular mechanisms of SQP were validated using cell counting kit-8 assay, flow cytometry, and western blotting with HK-2 cells as a model. Results: Network pharmacology analysis showed that 26 compounds and 207 potential targets of SQP were involved in the treatment of DKD; boldine, denudatin B, pinocembrin, kaempferoid, and quercetin were considered core compounds, and epidermal growth factor receptor (EGFR) and proto-oncogene, non-receptor tyrosine kinase (SRC) were considered key targets. Gene Ontology enrichment analysis indicated that protein phosphorylation and negative regulation of apoptotic processes are important biological processes in the treatment of DKD by SQP. Molecular docking confirmed the excellent binding abilities of boldine, denudatin B, kaempferide, and quercetin to EGFR and SRC. The results of in vitro experiments showed that treatment with an ethanolic extract of SQP significantly protected HK-2 cells from high glucose-induced cell damage. In addition, the SQP ethanol extract inhibited the phosphorylation of EGFR and SRC, suppressed the apoptosis rate, and regulated apoptosis-related proteins in HK-2 cells under high glucose stress. Conclusion: This study systematically and intuitively illustrated the possible pharmacological mechanisms of SQP against DKD through multiple components, targets, and signalling pathways, especially the inhibition of EGFR and SRC phosphorylation and apoptosis.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Investigating the mechanism of Fuling-Banxia-Dafupi in the treatment of diabetic kidney disease using network pharmacology and molecular docking
    Wang, Qi
    Pang, Yiran
    Yang, Han
    Zhang, Xin
    Nie, Weichen
    Zhou, Jiahui
    Chen, Rui
    NATURAL PRODUCT RESEARCH, 2024,
  • [22] Exploring the molecular mechanism of Epimedium for the treatment of ankylosing spondylitis based on network pharmacology, molecular docking, and molecular dynamics simulations
    Wang, Xiangjin
    Wu, Lijiao
    Yu, Maobin
    Wang, Hao
    He, Langyu
    Hu, Yilang
    Li, Zhaosen
    Zheng, Yuqin
    Peng, Bo
    MOLECULAR DIVERSITY, 2025, 29 (01) : 591 - 606
  • [23] Molecular mechanism of lycorine in the treatment of glioblastoma based on network pharmacology and molecular docking
    Jie Su
    Mengmeng Huo
    Fengnan Xu
    Liqiong Ding
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397 : 1551 - 1559
  • [24] Network pharmacology and molecular docking of endogenous active metabolites in diabetic kidney disease
    Xie, Xinmiao
    Wang, Yanzhe
    Chen, Sijia
    Liu, Yuyuan
    Li, Fengqin
    Zeng, Chuchu
    Zhang, Ling
    Wang, Xiaoxia
    RENAL FAILURE, 2023, 45 (02)
  • [25] Molecular mechanism of lycorine in the treatment of glioblastoma based on network pharmacology and molecular docking
    Su, Jie
    Huo, Mengmeng
    Xu, Fengnan
    Ding, Liqiong
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (03) : 1551 - 1559
  • [26] Molecular mechanism of Acanthopanax senticosus in the treatment of Alzheimer's disease based on network pharmacology and molecular docking
    Kuang, Feng
    Xiang, Tao
    MOLECULAR DIVERSITY, 2023, 27 (06) : 2849 - 2865
  • [27] Molecular mechanism of Acanthopanax senticosus in the treatment of Alzheimer’s disease based on network pharmacology and molecular docking
    Feng Kuang
    Tao Xiang
    Molecular Diversity, 2023, 27 : 2849 - 2865
  • [28] Exploring the Molecular Mechanisms of Herbs in the Treatment of Hyperlipidemia Based on Network Pharmacology and Molecular Docking
    Cheng, Xiao
    Sun, Geng
    Meng, Li
    Liu, Yueli
    Wen, Jiangnan
    Zhao, Xiaoli
    Cai, Wenhui
    Xin, Huawei
    Liu, Yu
    Hao, Chunxiang
    JOURNAL OF MEDICINAL FOOD, 2024, 27 (11) : 1092 - 1105
  • [29] The mechanism of Epimedium in the treatment of coronary atherosclerotic heart disease based on network pharmacology, molecular docking, and in vitro studies
    Xin, G.
    Yuedong, Y.
    Xuemei, S.
    Chenhan, M.
    Meng, Z.
    Chenbo, Z.
    Ning, G.
    Xindong, W.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (07) : 2478 - 2488
  • [30] Exploring the Mechanism of White Peony in the Treatment of Lupus Nephritis Based on Network Pharmacology and Molecular Docking
    Cao, Yao
    Wang, Chaoban
    Dong, Liqun
    ARCHIVOS ESPANOLES DE UROLOGIA, 2023, 76 (02): : 123 - 131